Tissue Repair Ltd (TRP) AI Stock Analysis

• Market Cap: AU$23.28M
• Dividend Yield: N/A
• Average Volume (3M): 93.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: 178.06%
• EPS Growth: -2.49%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 60,464,844
• 10 Day Avg. Volume: 171,402
• 30 Day Avg. Volume: 93,720
• PEG Ratio: -1.06
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 4.25
• P/FCF Ratio: -2.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: AU$0.38 ▼(-0.26% Downside)

The score is primarily held back by weak financial performance driven by sustained losses and negative free cash flow (cash runway/funding risk), despite strong recent revenue growth and a debt-free balance sheet. Technicals add support due to a clear uptrend and positive momentum signals, while valuation is constrained by negative earnings and no dividend.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, supporting long-term business expansion.

Debt-Free Balance Sheet

A debt-free balance sheet reduces financial risk and provides flexibility for strategic investments and growth initiatives.

Clinical Trial Progress

Advancements in clinical trials and strategic partnerships enhance product pipeline potential, supporting future revenue streams.

Negative Factors

Persistent Operating Losses

Ongoing operating losses reflect challenges in achieving profitability, which could necessitate future funding and impact sustainability.

Negative Cash Flow

Negative cash flow indicates high cash burn, posing risks to financial stability and potentially requiring external financing.

Equity Decline

Declining equity suggests erosion of shareholder value, highlighting the need for improved financial performance to restore confidence.

Tissue Repair Ltd Business Overview & Revenue Model

Company Description

Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.

How the Company Makes Money

Tissue Repair Ltd generates revenue primarily through the sale of its proprietary therapeutic products to hospitals, clinics, and healthcare providers. These products are marketed and distributed both directly and through strategic partnerships with pharmaceutical companies and medical device distributors. TRP also earns income through licensing agreements, where it grants rights to other companies to use its patented technologies in exchange for royalties or upfront payments. Additionally, TRP may receive funding through research grants and collaborations with academic institutions or government agencies, which support the development of new therapies and expand its product pipeline.

Tissue Repair Ltd Financial Statement Overview

Summary

Tissue Repair Ltd shows strong revenue growth but struggles with negative net income and cash flow issues. The balance sheet is strong due to no debt and robust equity, but the company's inability to generate returns and negative cash flow limits financial stability.

Income Statement

Tissue Repair Ltd has shown significant revenue growth from 2023 to 2024, indicating potential market acceptance. However, the company continues to suffer from negative net income and EBIT, which suggests ongoing operational challenges with profitability. The gross profit margin is high, but net profit margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a low-risk balance sheet. The equity ratio is robust, highlighting a solid capital structure. However, the company's ability to generate returns on equity is hampered by consistent net losses.

Cash Flow

Operating cash flow remains negative, indicating cash burn issues. Free cash flow has deteriorated over the year, reflecting increased operational cash outflows. The lack of financing cash flow suggests limited external funding, which could pose liquidity risks if negative cash flows continue.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.63M	2.63M	152.24K	3.08K	171.92K	152.64K
Gross Profit	2.63M	2.63M	150.51K	428.00	170.21K	152.64K
EBITDA	-4.72M	-4.72M	-6.51M	-5.14M	-7.01M	-189.44K
Net Income	-4.24M	-4.24M	-4.14M	-4.17M	-6.84M	-915.23K
Balance Sheet
Total Assets	14.57M	14.57M	19.39M	22.38M	25.90M	27.61M
Cash, Cash Equivalents and Short-Term Investments	12.32M	12.32M	16.44M	21.40M	25.46M	27.11M
Total Debt	0.00	0.00	0.00	0.00	0.00	7.50M
Total Liabilities	662.53K	662.53K	1.35M	497.35K	559.64K	536.00K
Stockholders Equity	13.91M	13.91M	18.04M	21.88M	25.34M	27.07M
Cash Flow
Free Cash Flow	-4.12M	-4.12M	-4.95M	-4.26M	-3.97M	-852.89K
Operating Cash Flow	-3.70M	-3.70M	-4.95M	-4.26M	-3.97M	-852.89K
Investing Cash Flow	-421.67K	-421.67K	-3.35K	-2.24K	-3.92K	5.00K
Financing Cash Flow	0.00	0.00	0.00	0.00	21.36M	7.46M

Tissue Repair Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Positive. The current price of 0.38 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.33, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 42.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:TRP.

Tissue Repair Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRP	51 Neutral	AU$23.28M	-5.42	-26.53%	―	178.06%	-2.49%
PTX	50 Neutral	AU$84.12M	-9.67	-49.72%	―	―	10.78%
AVE	44 Neutral	AU$36.73M	-9.09	-143.71%	―	306.88%	―
BGT	41 Neutral	AU$7.02M	-1.89	―	―	―	―
1AD	37 Underperform	AU$11.48M	-1.61	-628.72%	―	―	31.87%

Tissue Repair Ltd Corporate Events

Tissue Repair Limited Addresses ASX Price Query

Tissue Repair Limited has responded to an ASX price query, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company asserts compliance with listing rules and confirms that its responses have been authorized under its continuous disclosure policy.

Tissue Repair Ltd Announces Director’s Acquisition of Unlisted Options

Tissue Repair Ltd has announced a change in the director’s interest, specifically involving Patryk Kania, who has acquired 261,000 unlisted options. These options are exercisable at $1.15 and will expire on 26 November 2040, following approval at the company’s Annual General Meeting. This change reflects a strategic move in the company’s governance and could potentially impact its market operations by aligning director interests with long-term company performance.

Tissue Repair Ltd Announces Director’s Interest Change

Tissue Repair Ltd announced a change in the director’s interest, with Alistair McKeough acquiring 311,000 unlisted options and 30,000 ordinary fully paid shares. This change, approved by shareholders, reflects the company’s ongoing efforts to align its leadership’s interests with its strategic goals, potentially impacting its market positioning and stakeholder confidence.

Tissue Repair Limited Appoints New Auditor

Tissue Repair Limited has announced the appointment of Stantons International Audit and Consulting Pty Ltd as its new auditor, following the resignation of Pitcher Partners Sydney. This change, approved at the company’s Annual General Meeting, aligns with compliance requirements and has received necessary regulatory approvals. The appointment is expected to support the company’s ongoing operations and strategic goals.

Tissue Repair Ltd Successfully Passes All Resolutions at 2025 AGM

Tissue Repair Limited announced that all resolutions proposed at its 2025 Annual General Meeting were successfully carried. This includes the adoption of the remuneration report, election of new directors, appointment of auditors, and approval of options and incentive plans. The outcomes of these resolutions are expected to strengthen the company’s governance and operational strategies, potentially enhancing its market position and stakeholder confidence.

Tissue Repair Ltd Advances Clinical Trials and Expands Market Reach

Tissue Repair Ltd reported progress in its clinical trials for TR987®, with significant advancements in patient randomization and site activations across the U.S. and Australia. The company is on track with its regulatory submissions and has commenced a partnership with Advanced Cosmeceuticals Pty Ltd for TR Pro+®, expecting meaningful sales to begin in early 2026. Financially, the company reported a cash position of $10.3 million as of September 2025, with increased revenue from TR Pro+® sales and ongoing R&D investments.

Tissue Repair Limited Announces 2025 Annual General Meeting

Tissue Repair Limited has announced its Annual General Meeting, scheduled for November 24, 2025, in Sydney. The meeting will allow shareholders to vote on significant company decisions, emphasizing the importance of shareholder participation in shaping the company’s future. The company is providing electronic access to the meeting notice and proxy voting options to facilitate shareholder engagement.